Plain-English translation of NCT06850623 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination treatment for pancreatic cancer that cannot be surgically removed. The treatment pairs PS101 (a medication injected into the tumor) with focused ultrasound waves, given alongside standard chemotherapy drugs. Researchers want to see if this combination approach can shrink tumors and help patients live longer.
Pancreatic cancer that has grown too large or spread too far to be safely removed by surgery is very difficult to treat. Current chemotherapy alone has limited effectiveness, so doctors are exploring whether adding ultrasound-guided therapy might help the medication work better and improve outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive treatment over about 16 weeks in eight 2-week cycles. On the first day of each cycle, you would receive the ultrasound-guided therapy in the hospital, followed by chemotherapy infusions. You would have regular check-in visits to monitor how you're doing and watch for side effects, and imaging scans every 8 weeks to see how well the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States